Department of Surgery, Mayo Clinic, Scottsdale, AZ, USA.
Ann Surg Oncol. 2010 Sep;17(9):2419-26. doi: 10.1245/s10434-010-1016-1. Epub 2010 Mar 16.
Patients with metastatic or stage IV breast cancer have limited therapeutic options, and the mainstay of treatment remains systemic chemotherapy. Traditionally, the role of surgery has been confined to strict palliation. Improvements in the efficacy of chemotherapeutic regimens, coupled with the use of hormonal and targeted therapy, have resulted in an expansion of surgical resection beyond simple palliation. Several single-institution studies have reported improved survival and even long-term cures after surgical resection for oligometastatic stage IV breast cancer. Similarly, provocative new data suggest that removal of the primary tumor in some patients may confer a survival advantage. The aim of this review is to summarize studies in the medical literature pertaining to the use of surgical resection in patients with stage IV breast cancer. We believe there is enough evidence to challenge conventional thinking about the role of surgery in stage IV breast cancer and to consider a new multimodality treatment paradigm to optimize patient outcomes. It is time to conduct a carefully designed randomized trial to see whether surgery in stage IV breast cancer does indeed warrant a second look.
转移性或 IV 期乳腺癌患者的治疗选择有限,主要治疗方法仍然是全身化疗。传统上,手术的作用仅限于严格的姑息治疗。化疗方案疗效的提高,加上激素和靶向治疗的应用,使得手术切除的范围超出了单纯的姑息治疗。一些单中心研究报告称,对寡转移性 IV 期乳腺癌患者进行手术切除可提高生存率,甚至实现长期治愈。同样,令人振奋的新数据表明,某些患者切除原发肿瘤可能会带来生存优势。本文旨在对医学文献中关于手术切除在 IV 期乳腺癌患者中的应用的研究进行总结。我们认为,有足够的证据可以挑战传统上对 IV 期乳腺癌手术作用的看法,并考虑一种新的多模式治疗方案来优化患者的预后。现在是时候进行精心设计的随机试验,看看 IV 期乳腺癌的手术是否确实值得重新审视。